133 related articles for article (PubMed ID: 24165098)
1. Biological activity of sporolides A and B from Salinispora tropica: in silico target prediction using ligand-based pharmacophore mapping and in vitro activity validation on HIV-1 reverse transcriptase.
Dineshkumar K; Aparna V; Madhuri KZ; Hopper W
Chem Biol Drug Des; 2014 Mar; 83(3):350-61. PubMed ID: 24165098
[TBL] [Abstract][Full Text] [Related]
2. A pharmacophore docking algorithm and its application to the cross-docking of 18 HIV-NNRTI's in their binding pockets.
Daeyaert F; de Jonge M; Heeres J; Koymans L; Lewi P; Vinkers MH; Janssen PA
Proteins; 2004 Feb; 54(3):526-33. PubMed ID: 14748000
[TBL] [Abstract][Full Text] [Related]
3. Molecular modeling, synthesis and biological evaluation of N-heteroaryl compounds as reverse transcriptase inhibitors against HIV-1.
Singh A; Yadav D; Yadav M; Dhamanage A; Kulkarni S; Singh RK
Chem Biol Drug Des; 2015 Mar; 85(3):336-47. PubMed ID: 25055732
[TBL] [Abstract][Full Text] [Related]
4. Synthesis, biological activity and docking study of imidazol-5-one as novel non-nucleoside HIV-1 reverse transcriptase inhibitors.
Mokale SN; Lokwani D; Shinde DB
Bioorg Med Chem; 2012 May; 20(9):3119-27. PubMed ID: 22480850
[TBL] [Abstract][Full Text] [Related]
5. Per-residue energy decomposition pharmacophore model to enhance virtual screening in drug discovery: a study for identification of reverse transcriptase inhibitors as potential anti-HIV agents.
Cele FN; Ramesh M; Soliman ME
Drug Des Devel Ther; 2016; 10():1365-77. PubMed ID: 27114700
[TBL] [Abstract][Full Text] [Related]
6. Assessing molecular docking tools for relative biological activity prediction: a case study of triazole HIV-1 NNRTIs.
Frączek T; Siwek A; Paneth P
J Chem Inf Model; 2013 Dec; 53(12):3326-42. PubMed ID: 24266618
[TBL] [Abstract][Full Text] [Related]
7. Molecular Docking and Molecular Dynamics Simulation Based Approach to Explore the Dual Inhibitor Against HIV-1 Reverse Transcriptase and Integrase.
Chander S; Pandey RK; Penta A; Choudhary BS; Sharma M; Malik R; Prajapati VK; Murugesan S
Comb Chem High Throughput Screen; 2017; 20(8):734-746. PubMed ID: 28641512
[TBL] [Abstract][Full Text] [Related]
8. Combined approach using ligand efficiency, cross-docking, and antitarget hits for wild-type and drug-resistant Y181C HIV-1 reverse transcriptase.
García-Sosa AT; Sild S; Takkis K; Maran U
J Chem Inf Model; 2011 Oct; 51(10):2595-611. PubMed ID: 21875140
[TBL] [Abstract][Full Text] [Related]
9. Novel piperidinylamino-diarylpyrimidine derivatives with dual structural conformations as potent HIV-1 non-nucleoside reverse transcriptase inhibitors.
Chen X; Liu X; Meng Q; Wang D; Liu H; De Clercq E; Pannecouque C; Balzarini J; Liu X
Bioorg Med Chem Lett; 2013 Dec; 23(24):6593-7. PubMed ID: 24239481
[TBL] [Abstract][Full Text] [Related]
10. Docking and quantitative structure-activity relationship studies for the bisphenylbenzimidazole family of non-nucleoside inhibitors of HIV-1 reverse transcriptase.
Lagos CF; Caballero J; Gonzalez-Nilo FD; David Pessoa-Mahana C; Perez-Acle T
Chem Biol Drug Des; 2008 Nov; 72(5):360-9. PubMed ID: 19012572
[TBL] [Abstract][Full Text] [Related]
11. In silico screening for non-nucleoside HIV-1 reverse transcriptase inhibitors using physicochemical filters and high-throughput docking followed by in vitro evaluation.
Bustanji Y; Al-Masri IM; Qasem A; Al-Bakri AG; Taha MO
Chem Biol Drug Des; 2009 Sep; 74(3):258-65. PubMed ID: 19703027
[TBL] [Abstract][Full Text] [Related]
12. Design and synthesis of N₁-aryl-benzimidazoles 2-substituted as novel HIV-1 non-nucleoside reverse transcriptase inhibitors.
Monforte AM; Ferro S; De Luca L; Lo Surdo G; Morreale F; Pannecouque C; Balzarini J; Chimirri A
Bioorg Med Chem; 2014 Feb; 22(4):1459-67. PubMed ID: 24457088
[TBL] [Abstract][Full Text] [Related]
13. Identification of HIV-1 reverse transcriptase dual inhibitors by a combined shape-, 2D-fingerprint- and pharmacophore-based virtual screening approach.
Distinto S; Esposito F; Kirchmair J; Cardia MC; Gaspari M; Maccioni E; Alcaro S; Markt P; Wolber G; Zinzula L; Tramontano E
Eur J Med Chem; 2012 Apr; 50():216-29. PubMed ID: 22361685
[TBL] [Abstract][Full Text] [Related]
14. Ligand Based-Pharmacophore Modeling and Extended Bi oactivity Prediction for Salinosporamide A, B and C from Marine Actino mycetes Salinispora tropica.
Dineshkumar K; Vasudevan A; Hopper W
Comb Chem High Throughput Screen; 2017; 20(1):3-19. PubMed ID: 28000560
[TBL] [Abstract][Full Text] [Related]
15. Dual inhibitor design for HIV-1 reverse transcriptase and integrase enzymes: a molecular docking study.
Ercan S; Şenyiğit B; Şenses Y
J Biomol Struct Dyn; 2020 Feb; 38(2):573-580. PubMed ID: 31787027
[TBL] [Abstract][Full Text] [Related]
16. HIV-reverse transcriptase inhibition: inclusion of ligand-induced fit by cross-docking studies.
Ragno R; Frasca S; Manetti F; Brizzi A; Massa S
J Med Chem; 2005 Jan; 48(1):200-12. PubMed ID: 15634014
[TBL] [Abstract][Full Text] [Related]
17. Arylthiopyrrole (AThP) derivatives as non-nucleoside HIV-1 reverse transcriptase inhibitors: synthesis, structure-activity relationships, and docking studies (part 2).
Lavecchia A; Costi R; Artico M; Miele G; Novellino E; Bergamini A; Crespan E; Maga G; Di Santo R
ChemMedChem; 2006 Dec; 1(12):1379-90. PubMed ID: 17089434
[TBL] [Abstract][Full Text] [Related]
18. Revealing interaction mode between HIV-1 reverse transcriptase and diaryltriazine analog inhibitor.
Li Z; Han J; Chen HF
Chem Biol Drug Des; 2008 Nov; 72(5):350-9. PubMed ID: 19012571
[TBL] [Abstract][Full Text] [Related]
19. Relative free energy of binding and binding mode calculations of HIV-1 RT inhibitors based on dock-MM-PB/GS.
Zhou Z; Madura JD
Proteins; 2004 Nov; 57(3):493-503. PubMed ID: 15382241
[TBL] [Abstract][Full Text] [Related]
20. Synthesis, biological evaluation and molecular modeling studies of N-aryl-2-arylthioacetamides as non-nucleoside HIV-1 reverse transcriptase inhibitors.
Xiaohe Z; Yu Q; Hong Y; Xiuqing S; Rugang Z
Chem Biol Drug Des; 2010 Oct; 76(4):330-9. PubMed ID: 20731670
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
